

Andrew T Parsa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11122479/publications.pdf>

Version: 2024-02-01

182
papers

16,200
citations

14644

66
h-index

17090

122
g-index

183
all docs

183
docs citations

183
times ranked

17738
citing authors

#	ARTICLE	IF	CITATIONS
1	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
2	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3575-3584.	3.2	78
3	In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. <i>Neurosurgery</i> , 2017, 81, E32-E32.	0.6	0
4	Safety and outcomes of preoperative embolization of intracranial hemangioblastomas: A systematic review. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 143-151.	0.6	35
5	Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. <i>World Neurosurgery</i> , 2016, 95, 368-374.	0.7	26
6	Immunomonitoring in glioma immunotherapy: current status and future perspectives. <i>Journal of Neuro-Oncology</i> , 2016, 127, 1-13.	1.4	20
7	Role of preoperative embolization for intradural spinal hemangioblastomas. <i>Journal of Clinical Neuroscience</i> , 2016, 24, 83-87.	0.8	15
8	The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors. <i>Journal of Neuroimmunology</i> , 2016, 290, 103-108.	1.1	25
9	Predictors of recurrence in the management of chordoid meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 107-116.	1.4	24
10	Pigmented villonodular synovitis of the temporomandibular joint with intracranial extension: A case series and systematic review. <i>Head and Neck</i> , 2015, 37, 1213-1224.	0.9	46
11	Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells. <i>PLoS ONE</i> , 2015, 10, e0111532.	1.1	19
12	Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. <i>Neurosurgery</i> , 2015, 76, 179-186.	0.6	72
13	Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α . <i>Neuro-Oncology</i> , 2015, 17, 832-842.	0.6	18
14	Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 48-54.	0.8	129
15	Management of central nervous system teratoma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 98-104.	0.8	17
16	Tumor-to-tumor metastasis: Breast carcinoma to meningioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 268-274.	0.8	29
17	Heat shock protein vaccines against glioblastoma: from bench to bedside. <i>Journal of Neuro-Oncology</i> , 2015, 123, 441-448.	1.4	63
18	Quality Improvement in Neurosurgery. <i>Neurosurgery Clinics of North America</i> , 2015, 26, xiii-xiv.	0.8	8

#	ARTICLE	IF	CITATIONS
19	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1964-1968.	0.8	61
20	Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: A systematic review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2015, 138, 129-136.	0.6	32
21	Association of tumor location, extent of resection, and neurofibromatosis status with clinical outcomes for 221 spinal nerve sheath tumors. <i>Neurosurgical Focus</i> , 2015, 39, E5.	1.0	43
22	Vaccine Therapies in Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 508.	2.0	21
23	The current trend of administering a patient-generated index in the oncological setting: a systematic review. <i>Oncology Reviews</i> , 2014, 8, 245.	0.8	11
24	The role of epidermal growth factor-like module containing mucin-like hormone receptor 2 in human cancers. <i>Oncology Reviews</i> , 2014, 8, 242.	0.8	5
25	PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. <i>Immunotherapy</i> , 2014, 6, 737-753.	1.0	17
26	Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. <i>Neuro-Oncology</i> , 2014, 16, 628-636.	0.6	166
27	Surgery is cost-effective treatment for young patients with vestibular schwannomas: decision tree modeling of surgery, radiation, and observation. <i>Neurosurgical Focus</i> , 2014, 37, E8.	1.0	32
28	Intramenigeoma Metastasis of Breast Carcinoma. <i>Rare Tumors</i> , 2014, 6, 49-52.	0.3	14
29	Medical errors in neurosurgery. , 2014, 5, 435.		24
30	GLIOMAS PROMOTE INDUCTION OF B7-H1/PD-L1 EXPRESSION ON MONOCYTES: CLINICAL EVIDENCE OF AN IMMUNOSUPPRESSIVE MECHANISM THAT CAN BE TARGETED WITH ANTIBODY BLOCKADE. <i>Neuro-Oncology</i> , 2014, 16, iii41-iii41.	0.6	1
31	Surgical outcomes in spinal cord ependymomas and the importance of extent of resection in children and young adults. <i>Journal of Neurosurgery: Pediatrics</i> , 2014, 13, 393-399.	0.8	39
32	Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. <i>Journal of Neurosurgery</i> , 2014, 120, 736-745.	0.9	155
33	Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial. <i>Neuro-Oncology</i> , 2014, 16, 758-759.	0.6	18
34	Management of Planum/Olfactory Meningiomas: Predicting Symptoms and Postoperative Complications. <i>World Neurosurgery</i> , 2014, 82, 1216-1223.	0.7	15
35	Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2129-2134.	0.8	12
36	Prognosis by tumor location in adults with intracranial ependymomas. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2096-2101.	0.8	41

#	ARTICLE	IF	CITATIONS
37	Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 345.	1.8	21
38	NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with <i>EGFR</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2919-2929.	1.9	17
39	Surgical risk factors for post-operative pneumonia following meningioma resection. <i>Clinical Neurology and Neurosurgery</i> , 2014, 118, 76-79.	0.6	21
40	Systematic Review of Protein Biomarkers of Invasive Behavior in Glioblastoma. <i>Molecular Neurobiology</i> , 2014, 49, 1212-1244.	1.9	28
41	Intraventricular neurocytomas: A systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors. <i>Clinical Neurology and Neurosurgery</i> , 2014, 117, 55-64.	0.6	29
42	Complement anaphylatoxins as immune regulators in cancer. <i>Cancer Medicine</i> , 2014, 3, 747-758.	1.3	41
43	Heat-shock protein peptide complex ⁹⁶ vaccination for recurrent glioblastoma: a phase II, single-arm trial. <i>Neuro-Oncology</i> , 2014, 16, 274-279.	0.6	188
44	Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence. <i>Journal of Neurosurgery</i> , 2014, 121, 1139-1147.	0.9	52
45	Towards a hypermodern theory of meningioma surgery. <i>Clinical Neurology and Neurosurgery</i> , 2014, 126, 69-75.	0.6	3
46	Vaccine therapies for patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 119, 531-546.	1.4	32
47	Pleomorphic xanthoastrocytomas: Institutional experience of 18 patients. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1767-1772.	0.8	21
48	What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients?. <i>Journal of Neurosurgery</i> , 2014, 121, 908-918.	0.9	63
49	Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12823-12828.	3.3	146
50	Immunocompetent murine models for the study of glioblastoma immunotherapy. <i>Journal of Translational Medicine</i> , 2014, 12, 107.	1.8	175
51	Principles of Surgery for Malignant Astrocytomas. <i>Seminars in Oncology</i> , 2014, 41, 523-531.	0.8	4
52	Fractionated radiation therapy for vestibular schwannoma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1083-1088.	0.8	13
53	Facial neuroma masquerading as acoustic neuroma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1817-1818.	0.8	2
54	Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 116-120.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Modern treatment of 84 newly diagnosed craniopharyngiomas. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1558-1566.	0.8	17
56	Spinal ependymomas: Benefits of extent of resection for different histological grades. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1390-1397.	0.8	39
57	Surgical outcomes in choroid plexus papillomas: an institutional experience. <i>Journal of Neuro-Oncology</i> , 2013, 113, 117-125.	1.4	29
58	Na ⁺ /K ⁺ -ATPase α 2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells. <i>Neuro-Oncology</i> , 2013, 15, 1518-1531.	0.6	30
59	Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein. <i>Clinical Cancer Research</i> , 2013, 19, 205-214.	3.2	158
60	Disseminated progression of glioblastoma after treatment with bevacizumab. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1795-1801.	0.6	19
61	Falcine and parasagittal chondrosarcomas. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1232-1236.	0.8	9
62	G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1014-1018.	0.8	32
63	The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 281-286.	0.8	51
64	Skull Base Chondrosarcoma. <i>Neurosurgery Clinics of North America</i> , 2013, 24, 89-96.	0.8	69
65	Modern surgical outcomes following surgery for sphenoid wing meningiomas. <i>Journal of Neurosurgery</i> , 2013, 119, 86-93.	0.9	40
66	Prognosis by tumor location in adults with spinal ependymomas. <i>Journal of Neurosurgery: Spine</i> , 2013, 18, 226-235.	0.9	59
67	A Spheroid Weighted-Axis Converter of Vestibular Schwannoma Size. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 108-114.	1.1	6
68	Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. <i>Neuro-Oncology</i> , 2013, 15, 208-215.	0.6	70
69	Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages. <i>Clinical Cancer Research</i> , 2013, 19, 3165-3175.	3.2	393
70	Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis. <i>Neuro-Oncology</i> , 2013, 15, 255-267.	0.6	78
71	Pathology of Spinal Ependymomas. <i>Neurosurgery</i> , 2013, 73, 247-255.	0.6	50
72	Mannose-Binding Lectin 2 Gene and Risk of Adult Glioma. <i>PLoS ONE</i> , 2013, 8, e61117.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients. <i>PLoS ONE</i> , 2013, 8, e62765.	1.1	44
74	Association of Morbidity with Extent of Resection and Cavernous Sinus Invasion in Sphenoid Wing Meningiomas. <i>Skull Base</i> , 2012, 21, e5-e5.	0.4	1
75	Regional variation in histopathologic features of tumor specimens from treatment-naïve glioblastoma correlates with anatomic and physiologic MR Imaging. <i>Neuro-Oncology</i> , 2012, 14, 942-954.	0.6	183
76	Neuroanatomical correlation of the House-Brackmann grading system in the microsurgical treatment of vestibular schwannoma. <i>Neurosurgical Focus</i> , 2012, 33, E7.	1.0	16
77	Association of Morbidity with Extent of Resection and Cavernous Sinus Invasion in Sphenoid Wing Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2012, 73, 076-083.	0.4	12
78	Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. <i>Neuro-Oncology</i> , 2012, 14, 584-595.	0.6	120
79	Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment. <i>Neurosurgery</i> , 2012, 70, 361-370.	0.6	60
80	Reporting Standard Compliance in Publications of Vestibular Schwannoma Patients Treated With Microsurgery. <i>Otology and Neurotology</i> , 2012, 33, 648-650.	0.7	6
81	Immunotherapy for Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 357-370.	0.8	36
82	Impact of extent of resection for recurrent glioblastoma on overall survival. <i>Journal of Neurosurgery</i> , 2012, 117, 1032-1038.	0.9	370
83	The effect of the 2003 Consensus Reporting Standards on publications describing patients with vestibular schwannoma treated with stereotactic radiosurgery. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1144-1147.	0.8	7
84	Treatment-related morbidity and the management of pediatric craniopharyngioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2012, 10, 293-301.	0.8	77
85	Intracranial hemangiopericytoma. <i>Cancer</i> , 2012, 118, 1628-1636.	2.0	128
86	Stereotactic radiosurgery for benign meningiomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 13-20.	1.4	65
87	Heat shock protein-peptide complex in the treatment of glioblastoma. <i>Expert Review of Vaccines</i> , 2011, 10, 721-731.	2.0	23
88	Preface. <i>Neurosurgery Clinics of North America</i> , 2011, 22, xi.	0.8	1
89	Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. <i>Journal of Neurosurgery</i> , 2011, 114, 566-573.	0.9	253
90	An extent of resection threshold for newly diagnosed glioblastomas. <i>Journal of Neurosurgery</i> , 2011, 115, 3-8.	0.9	1,323

#	ARTICLE	IF	CITATIONS
91	The molecular pathology of central neurocytomas. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1-6.	0.8	22
92	Clinical and surgical considerations for cerebellopontine angle meningiomas. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 755-759.	0.8	27
93	Signaling pathways in cranial chondrosarcoma: potential molecular targets for directed chemotherapy. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 881-885.	0.8	18
94	Awake far lateral craniotomy for resection of foramen magnum meningioma in a patient with tenuous motor and somatosensory evoked potentials. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1254-1256.	0.8	13
95	Implications of Cystic Features in Vestibular Schwannomas of Patients Undergoing Microsurgical Resection. <i>Neurosurgery</i> , 2011, 68, 874-880.	0.6	33
96	Embolization of Skull Base Meningiomas and Feeding Vessels Arising From the Internal Carotid Circulation. <i>Neurosurgery</i> , 2011, 68, 162-169.	0.6	59
97	Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 463-476.	1.4	109
98	Factors associated with preservation of facial nerve function after surgical resection of vestibular schwannoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 281-286.	1.4	80
99	Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 165-171.	1.4	20
100	Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 317-323.	1.4	5
101	Anatomic location is a risk factor for atypical and malignant meningiomas. <i>Cancer</i> , 2011, 117, 1272-1278.	2.0	164
102	Beyond audiofacial morbidity after vestibular schwannoma surgery. <i>Journal of Neurosurgery</i> , 2011, 114, 367-374.	0.9	82
103	Impact of bevacizumab chemotherapy on craniotomy wound healing. <i>Journal of Neurosurgery</i> , 2011, 114, 1609-1616.	0.9	93
104	Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated?. <i>Journal of Neurosurgery</i> , 2011, 114, 705-709.	0.9	70
105	Results with judicious modern neurosurgical management of parasagittal and falcine meningiomas. <i>Journal of Neurosurgery</i> , 2011, 114, 731-737.	0.9	58
106	Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. <i>Journal of Neurosurgery</i> , 2011, 115, 505-511.	0.9	102
107	Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. <i>Journal of Neurosurgery</i> , 2011, 114, 386-393.	0.9	44
108	A prospective study of hearing preservation in untreated vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2011, 114, 381-385.	0.9	77

#	ARTICLE	IF	CITATIONS
109	Extent of resection and the long-term durability of vestibular schwannoma surgery. <i>Journal of Neurosurgery</i> , 2011, 114, 1218-1223.	0.9	85
110	Risk factors for the development of serious medical complications after resection of meningiomas. <i>Journal of Neurosurgery</i> , 2011, 114, 697-704.	0.9	53
111	Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. <i>Journal of Neurosurgery</i> , 2011, 114, 359-366.	0.9	41
112	The molecular biology and novel treatments of vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2011, 115, 906-914.	0.9	58
113	A Critical Evaluation of Vestibular Schwannoma Surgery for Patients Younger Than 40 Years of Age. <i>Neurosurgery</i> , 2010, 67, 1646-1654.	0.6	18
114	Mapping Clinical Outcomes Expectations to Treatment Decisions. <i>Otology and Neurotology</i> , 2010, 31, 284-293.	0.7	26
115	EMR-3. <i>NeuroReport</i> , 2010, 21, 1018-1022.	0.6	22
116	The complement cascade as a mediator of tissue growth and regeneration. <i>Inflammation Research</i> , 2010, 59, 897-905.	1.6	109
117	Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. <i>Journal of Neuro-Oncology</i> , 2010, 98, 101-108.	1.4	68
118	Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. <i>Journal of Neuro-Oncology</i> , 2010, 96, 313-320.	1.4	128
119	Surgical Technique of Temporary Arterial Occlusion in the Operative Management of Spinal Hemangioblastomas. <i>World Neurosurgery</i> , 2010, 74, 200-205.	0.7	22
120	Ubiquitin-Specific Protease 8 Links the PTEN-Akt-AIP4 Pathway to the Control of FLIPs Stability and TRAIL Sensitivity in Glioblastoma Multiforme. <i>Cancer Research</i> , 2010, 70, 5046-5053.	0.4	63
121	The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. <i>Journal of Neurosurgery</i> , 2010, 112, 163-167.	0.9	168
122	A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. <i>Journal of Neurosurgery</i> , 2010, 112, 851-859.	0.9	142
123	Cancer and the Complement Cascade. <i>Molecular Cancer Research</i> , 2010, 8, 1453-1465.	1.5	206
124	Craniopharyngioma: a comparison of tumor control with various treatment strategies. <i>Neurosurgical Focus</i> , 2010, 28, E5.	1.0	163
125	Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. <i>Journal of Neurosurgery</i> , 2010, 112, 990-996.	0.9	49
126	Posttreatment prognosis of patients with esthesioneuroblastoma. <i>Journal of Neurosurgery</i> , 2010, 113, 340-351.	0.9	87

#	ARTICLE	IF	CITATIONS
127	Secondary gliosarcoma: a review of clinical features and pathological diagnosis. Journal of Neurosurgery, 2010, 112, 26-32.	0.9	49
128	Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. Journal of Neurosurgery, 2010, 113, 1087-1092.	0.9	67
129	TGF- β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncology, 2010, 12, 7-13.	0.6	267
130	Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. Journal of Neurosurgery, 2010, 113, 202-209.	0.9	134
131	Cranial Chondrosarcoma and Recurrence. Skull Base, 2010, 20, 149-156.	0.4	89
132	Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR Imaging. Radiology, 2010, 254, 564-576.	3.6	148
133	Treatment decision making based on the published natural history and growth rate of small meningiomas. Journal of Neurosurgery, 2010, 113, 1036-1042.	0.9	121
134	The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. Journal of Neurosurgery, 2010, 113, 1029-1035.	0.9	244
135	Monitoring Immune Responses After Glioma Vaccine Immunotherapy. Neurosurgery Clinics of North America, 2010, 21, 195-199.	0.8	6
136	Heat Shock Proteins in Glioblastomas. Neurosurgery Clinics of North America, 2010, 21, 111-123.	0.8	16
137	Predictors of mortality following treatment of intracranial hemangiopericytoma. Journal of Neurosurgery, 2010, 113, 333-339.	0.9	108
138	The role of microglia in central nervous system immunity and glioma immunology. Journal of Clinical Neuroscience, 2010, 17, 6-10.	0.8	301
139	Hearing preservation rates after microsurgical resection of vestibular schwannoma. Journal of Clinical Neuroscience, 2010, 17, 1126-1129.	0.8	67
140	CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. Journal of Clinical Neuroscience, 2010, 17, 1381-1385.	0.8	147
141	Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. Journal of Clinical Neuroscience, 2010, 17, 1543-1547.	0.8	30
142	Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy. Neurosurgery Clinics of North America, 2010, 21, 181-186.	0.8	39
143	Preservation of facial nerve function after resection of vestibular schwannoma. British Journal of Neurosurgery, 2010, 24, 666-671.	0.4	75
144	Intramedullary Spinal Cord Tumors. Pediatric Oncology, 2010, , 187-204.	0.5	2

#	ARTICLE	IF	CITATIONS
145	A Novel PTEN-Dependent Link to Ubiquitination Controls FLIPS Stability and TRAIL Sensitivity in Glioblastoma Multiforme. <i>Cancer Research</i> , 2009, 69, 7911-7916.	0.4	44
146	Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 579-584.	0.8	354
147	Flow cytometry and in vitro analysis of human glioma-associated macrophages. <i>Journal of Neurosurgery</i> , 2009, 110, 572-582.	0.9	150
148	Non-audiofacial morbidity after Gamma Knife surgery for vestibular schwannoma. <i>Neurosurgical Focus</i> , 2009, 27, E4.	1.0	54
149	Radiobiology of vestibular schwannomas: mechanisms of radioresistance and potential targets for therapeutic sensitization. <i>Neurosurgical Focus</i> , 2009, 27, E2.	1.0	37
150	Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. <i>Radiology</i> , 2009, 253, 486-496.	3.6	365
151	Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery. <i>Journal of Neuro-Oncology</i> , 2009, 93, 41-48.	1.4	126
152	Hearing preservation after stereotactic radiosurgery for vestibular schwannoma: A systematic review. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 742-747.	0.8	132
153	A systematic review of intracranial chondrosarcoma and survival. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1547-1551.	0.8	127
154	Immunological considerations of modern animal models of malignant primary brain tumors. <i>Journal of Translational Medicine</i> , 2009, 7, 84.	1.8	21
155	Honokiol-mediated Inhibition of PI3K/mTOR Pathway. <i>Journal of Immunotherapy</i> , 2009, 32, 585-592.	1.2	77
156	Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. <i>NeuroReport</i> , 2009, 20, 1597-1602.	0.6	37
157	AANS/CNS section on tumor satellite meeting. <i>Journal of Neuro-Oncology</i> , 2008, 87, 195-195.	1.4	0
158	Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. <i>Journal of Neurosurgery</i> , 2008, 109, 817-824.	0.9	226
159	Endoscopic Reconstruction of Skull Base Defects with the Nasal Septal Flap. <i>Skull Base</i> , 2008, 18, 385-394.	0.4	87
160	FLUCTUATING RESPONSE OF A CYSTIC VESTIBULAR SCHWANNOMA TO RADIOSURGERY. <i>Neurosurgery</i> , 2008, 62, E1164-E1165.	0.6	34
161	Modified Paramedian Transpedicular Approach and Spinal Reconstruction for Intradural Tumors of the Cervical and Cervicothoracic Spine. <i>Spine</i> , 2007, 32, E203-E210.	1.0	32
162	LACK OF B7 EXPRESSION, NOT HUMAN LEUKOCYTE ANTIGEN EXPRESSION, FACILITATES IMMUNE EVASION BY HUMAN MALIGNANT GLIOMAS. <i>Neurosurgery</i> , 2007, 60, 1129-1136.	0.6	37

#	ARTICLE	IF	CITATIONS
163	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. <i>Nature Medicine</i> , 2007, 13, 84-88.	15.2	1,177
164	Clinical Management of Intramedullary Spinal Ependymomas in Adults. <i>Neurosurgery Clinics of North America</i> , 2006, 17, 21-27.	0.8	25
165	Pathologic and Epidemiologic Findings of Intramedullary Spinal Cord Tumors. <i>Neurosurgery Clinics of North America</i> , 2006, 17, 7-11.	0.8	46
166	Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 20-28.	1.9	37
167	Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. <i>Journal of Neurosurgery</i> , 2005, 103, 428-438.	0.9	155
168	Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. <i>Journal of Neurosurgery</i> , 2005, 102, 622-628.	0.9	108
169	Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. <i>Neurosurgery</i> , 2005, 56, 982-93; discussion 982-93.	0.6	138
170	Intramedullary spinal cord tumors: molecular insights and surgical innovation. <i>Clinical Neurosurgery</i> , 2005, 52, 76-84.	0.2	28
171	Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. <i>Nature</i> , 2004, 427, 740-744.	13.7	1,231
172	Spinal Cord and Intradural-Extraparenchymal Spinal Tumors: Current Best Care Practices and Strategies. <i>Journal of Neuro-Oncology</i> , 2004, 69, 291-318.	1.4	132
173	Cooperative translational control of gene expression by Ras and Akt in cancer. <i>Trends in Molecular Medicine</i> , 2004, 10, 607-613.	3.5	51
174	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 77-87.	1.4	1
175	Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine. <i>Journal of Neuro-Oncology</i> , 2003, 64, 77-87.	1.4	5
176	Intraventricular neurocytomas. <i>Neurosurgery Clinics of North America</i> , 2003, 14, 483-508.	0.8	26
177	Changes in the Immunologic Phenotype of Human Malignant Glioma Cells after Passaging in Vitro. <i>Clinical Immunology</i> , 2002, 102, 84-95.	1.4	39
178	Radiosurgery for the Treatment of Recurrent Central Neurocytomas. <i>Neurosurgery</i> , 2001, 48, 1231-1238.	0.6	60
179	Limitations of the C6/Wistar Rat Intracerebral Glioma Model: Implications for Evaluating Immunotherapy. <i>Neurosurgery</i> , 2000, 47, 993-1000.	0.6	84
180	Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model. <i>Neurosurgery</i> , 2000, 47, 1391-1399.	0.6	34

#	ARTICLE	IF	CITATIONS
181	Intracerebral Clysis in a Rat Glioma Model. <i>Neurosurgery</i> , 2000, 46, 683-691.	0.6	87
182	Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model. <i>Neurosurgery</i> , 2000, 47, 1391-1399.	0.6	84